MXCT

Over the past six months, MaxCyte's stock price has been impacted by several events. The Q4 2025 earnings report on March 24, 2026, missed EPS and revenue forecasts, leading to a stock drop. On March 23, 2026, Parmeet Ahuja was appointed as Chief Financial Officer. In February 2026, MaxCyte launched its ExPERT DTx™ 96-well electroporation platform. On March 16, 2026, MaxCyte received a Nasdaq non-compliance notice due to its stock price falling below $1.00 per share. MaxCyte is scheduled to report its first-quarter 2026 financial results on May 12, 2026. As of May 8, 2026, the stock has seen an 11.21% increase in the past month, but a 65.51% decrease over the last 12 months, and a year-to-date return of -45.94%.